4/17
03:00 pm
imtx
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Low
Report
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
3/16
10:58 am
imtx
Immatics (IMTX) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Immatics (IMTX) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
3/15
04:20 pm
imtx
Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside [Yahoo! Finance]
Medium
Report
Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside [Yahoo! Finance]
3/13
02:48 pm
imtx
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate [Yahoo! Finance]
Low
Report
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate [Yahoo! Finance]
3/9
01:41 pm
imtx
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot [Seeking Alpha]
Low
Report
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot [Seeking Alpha]
3/9
02:04 am
imtx
Low
Report
3/5
07:41 am
imtx
Immatics Announces Full Year 2025 Financial Results and Business Update [Yahoo! Finance]
Low
Report
Immatics Announces Full Year 2025 Financial Results and Business Update [Yahoo! Finance]
3/5
07:00 am
imtx
Immatics Announces Full Year 2025 Financial Results and Business Update
Low
Report
Immatics Announces Full Year 2025 Financial Results and Business Update
3/1
01:10 am
imtx
Medium
Report
2/19
09:16 am
imtx
Immatics (NASDAQ:IMTX) was given a new $25.00 price target on by analysts at Mizuho.
Medium
Report
Immatics (NASDAQ:IMTX) was given a new $25.00 price target on by analysts at Mizuho.
1/24
05:08 am
imtx
Immatics (NASDAQ:IMTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Immatics (NASDAQ:IMTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.